R1 RCM Inc (NASDAQ:RCM) shares reached a new 52-week high on Friday . The stock traded as high as $13.09 and last traded at $13.02, with a volume of 626020 shares traded. The stock had previously closed at $12.84.
Several equities research analysts recently weighed in on the company. BidaskClub upgraded Misonix from a “buy” rating to a “strong-buy” rating in a report on Wednesday, July 3rd. Zacks Investment Research lowered ExlService from a “hold” rating to a “sell” rating in a report on Wednesday. Finally, Cantor Fitzgerald set a $9.00 target price on Evofem Biosciences and gave the stock a “buy” rating in a report on Friday, April 12th. Five equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. R1 RCM presently has an average rating of “Buy” and an average target price of $14.80.
The company has a debt-to-equity ratio of 118.26, a current ratio of 0.93 and a quick ratio of 0.93. The business has a 50-day moving average of $12.13. The firm has a market capitalization of $1.44 billion, a P/E ratio of -40.69 and a beta of 0.08.
R1 RCM (NASDAQ:RCM) last issued its quarterly earnings results on Thursday, May 9th. The financial services provider reported ($0.04) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.05) by $0.01. The company had revenue of $275.90 million for the quarter, compared to the consensus estimate of $266.37 million. R1 RCM had a negative return on equity of 118.28% and a negative net margin of 2.19%. The company’s revenue for the quarter was up 87.3% on a year-over-year basis. During the same period in the previous year, the business posted ($0.26) EPS. On average, analysts predict that R1 RCM Inc will post 0.13 earnings per share for the current year.
In other R1 RCM news, Director Charles J. Ditkoff sold 4,099 shares of R1 RCM stock in a transaction that occurred on Monday, June 3rd. The stock was sold at an average price of $11.72, for a total value of $48,040.28. Following the transaction, the director now directly owns 4,099 shares of the company’s stock, valued at approximately $48,040.28. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Insiders own 59.40% of the company’s stock.
Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Hennessy Advisors Inc. bought a new stake in shares of R1 RCM in the second quarter worth about $3,589,000. Campbell & CO Investment Adviser LLC bought a new position in shares of R1 RCM during the first quarter worth about $339,000. Elk Creek Partners LLC grew its holdings in shares of R1 RCM by 5.6% during the first quarter. Elk Creek Partners LLC now owns 1,779,374 shares of the financial services provider’s stock worth $17,207,000 after buying an additional 94,411 shares in the last quarter. Globeflex Capital L P bought a new position in shares of R1 RCM during the first quarter worth about $824,000. Finally, PNC Financial Services Group Inc. grew its holdings in shares of R1 RCM by 5,468.3% during the first quarter. PNC Financial Services Group Inc. now owns 415,564 shares of the financial services provider’s stock worth $4,020,000 after buying an additional 408,101 shares in the last quarter. Institutional investors and hedge funds own 69.69% of the company’s stock.
R1 RCM Company Profile (NASDAQ:RCM)
R1 RCM Inc provides revenue cycle management (RCM) for healthcare providers in the United States. It offers end-to-end RCM services to manage their revenue cycle operations, which encompass patient registration, insurance and benefit verification, medical treatment documentation and coding, and bill preparation and collection from patients and payers.
Further Reading: Capital Gains
Receive News & Ratings for R1 RCM Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for R1 RCM and related companies with MarketBeat.com's FREE daily email newsletter.